Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antihypertensive, renal, inflammatory and oxidative stress effects of amlodipine and azelnidipine in patients with essential hypertensive

Trial Profile

Antihypertensive, renal, inflammatory and oxidative stress effects of amlodipine and azelnidipine in patients with essential hypertensive

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine (Primary) ; Azelnidipine (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Nov 2012 New trial record
    • 04 Oct 2012 Results presented at the 24th Scientific Meeting of the International Society of Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top